| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 15.4 | 13.1 |
| Net income | -33.5 | -10.5 |
| EPS (diluted, $ a share) | $-0.10 | $-0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +17.7% |
|---|---|
| Operating margin | -224.5% |
10-Q filed with the SEC, NASDAQ: IVVD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Invivyd, Inc.: key numbers
- Share price
- $0.5377Close, Nov 16
- Market cap
- $159M
- Shares outstanding
- 295.63MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Invivyd, Inc.
All →Invivyd Financial Results
Invivyd reported Q3 2026 financial results, highlighted by $15.4 million in PEMGARDA net product revenue, representing 18% year-over-year growth. The company also announced that Phase 3 clinical trial data for VYD2311 is expected imminently following regulatory dialogue with the FDA regarding accelerated approval pathways.
- Term
- Q3 2026
“We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury.”
Marc Elia, Chairman and Chief Executive Officer
“PEMGARDA’s continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies.”
Bill Duke, Chief Financial Officer
Invivyd Clinical Trial Data
Invivyd announced positive topline results from its LIBERTY Phase 3 study, which demonstrated that its COVID-19 monoclonal antibody candidate, VYD2311, had safety and tolerability superior to an mRNA-based vaccine. The company plans to use data from LIBERTY and the ongoing DECLARATION pivotal study to support a Biologics License Application (BLA) submission to the FDA via the Accelerated Approval Program.
- Earnings call
- Sep 29, 2026, 8:30 AM ET